BofA Securities\, Credit Suisse\, Goldman Sachs see more upside for equities

BofA Securities, Credit Suisse, Goldman Sachs see more upside for equities

A BofA September Global Fund Manager Survey for September suggests that 58 per cent of those surveyed say the market is in a bull-phase - up from 25 per cent who believed so in May.

Topics
stock markets | Equity markets | Indian equity markets

Puneet Wadhwa  |  New Delhi 

Ongoing bull market phase 'longest and slowest', says Morgan Stanley
According to Goldman Sachs, markets currently are in the first phase of a new investment cycle, which it calls a ‘Hope’ rally.

Despite the sharp rally in most across the globe since their respective March 2020 low, most fund managers still remain bullish on the road ahead for this asset class. Though they do caution against the intermittent corrections, the overall bullish trend, they say, remains intact for now.

A September Global Fund Manager Survey for September suggests that 58 per cent of those surveyed say the market is in a bull-phase – up from 25 per cent who believed so in May.

BofA-ML-survey-table

224 panelists with $646 billion worth of assets under management (AUM) participated in the survey conducted between September 3 and September 10. 199 participants with $601 billion AUM responded to the Global FMS questions and 90 participants with $181 billion AUM responded to the Regional FMS questions, Securities said.

However, the sustainability of this recovery has led to a marginal rise in cash levels across fund managers surveyed - from 4.6 per cent earlier to 4.8 per cent in September. Preference to US equities, according to Securities, continued in September as well across most global fund managers over Europe, UK, and emerging (EMs). As a result, US tech stocks remained the most crowded trade.

BofA-ML-survey-table-1

Those at Wealth Management, too, echo a similar view. Though they expect the equities to do well on the back of accommodative central bank policies, especially the US (US Fed), they do caution against the lopsided valuation of US tech stocks.

“The recent correction in the US Equities, they caution, is a warning shot that a more pronounced consolidation could be in the offing after equity valuations became lofty over the past few months, with the US markets, in particular, becoming increasingly lopsided as the rally was concentrated in certain technology names,” wrote Jitendra Gohil, head of India equity research at Wealth Management in a September 15 co-authored note with Premal Kamdar.

As regards India, Wealth Management expects the equity market to see some downward pressure in the coming weeks as profit booking may set in.

“However, from a medium-term perspective, we still expect positive returns from equities as we believe equity as an asset class should see support from ultra-loose monetary policies by the major central banks. We recommend investors to use this weakness to build exposure to large private sector banks from a 12-18 months’ perspective,” they said.

According to Goldman Sachs, currently are in the first phase of a new investment cycle, which it calls a ‘Hope’ rally. Investors, it says, start to anticipate an economic recovery in this phase and is typically the strongest part of the cycle. The liquidity support from global central banks that has fueled this rally is likely to continue and the 'policy support' remains very supportive for risk assets, believes. Economic recovery, they believe, looks more durable as vaccines become more likely. On the other hand, 49 per cent of fund managers surveyed by BofA Securities in September said that the global economy was in the early-cycle phase versus 37 per cent who still believe that it is still in a recession.

“September FMS shows net 61 per cent of investors predict a U- or W-shape recovery vs 20 per cent saying V-shape,” BofA Securities said.

Read our full coverage on stock markets
First Published: Wed, September 16 2020. 12:45 IST
RECOMMENDED FOR YOU

BofA Securities\, Credit Suisse\, Goldman Sachs see more upside for equities

Over 30 vaccine candidates supported, 3 in advance trials, 4 in advanced pre-clinical stage: Govt
172@29@17@137!~!172@29@0@53!~!|news|india|over-30-vaccine-candidates-supported-3-in-advance-trials-4-in-advanced-pre-clinical-stage-govt-5847121.html!~!news|moneycontrol|com!~!|controller|infinite_scroll_article.php!~!is_mobile=false
Here is your gateway to a 1-year FREE MC Pro Subscription, by applying for an American Express® card. Apply Now!
you are here: HomeNewsIndia
Last Updated : Sep 16, 2020 02:20 PM IST | Source: PTI

Over 30 vaccine candidates supported, 3 in advance trials, 4 in advanced pre-clinical stage: Govt

Union Minister of State for Home Nityanand Rai also told the Rajya Sabha that 13 clinical trials of repurposed drugs have been undertaken to build a portfolio of therapeutic options for COVID-19 patients.

PTI

The government on Wednesday said more than 30 vaccine candidates for coronavirus have been supported, and three of them are in advance stages of trials now, while four are in advanced pre-clinical development stage.

Union Minister of State for Home Nityanand Rai also told the Rajya Sabha that 13 clinical trials of repurposed drugs have been undertaken to build a portfolio of therapeutic options for COVID-19 patients.

Follow our LIVE blog for the latest updates of the novel coronavirus pandemic

"More than 30 vaccine candidates have been supported which are in different stages of development, 3 candidates are in advanced stage of Phase I, II, III trials and more than 4 are in advanced pre-clinical development stage," he said.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Rai said a national expert group on vaccine administration for COVID-19 was constituted on August 7, under the NITI Aayog.

Follow our full coverage of the coronavirus pandemic here.
First Published on Sep 16, 2020 02:00 pm
Sections